Trials / Completed
CompletedNCT02514551
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 245 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma (GEJ).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ramucirumab | Administered IV |
| DRUG | Paclitaxel | Administered IV |
Timeline
- Start date
- 2015-10-12
- Primary completion
- 2017-10-27
- Completion
- 2018-12-28
- First posted
- 2015-08-03
- Last updated
- 2020-06-17
- Results posted
- 2018-12-19
Locations
52 sites across 11 countries: United States, Belgium, Canada, Czechia, Germany, Greece, Italy, Spain, Sweden, Turkey (Türkiye), Ukraine
Source: ClinicalTrials.gov record NCT02514551. Inclusion in this directory is not an endorsement.